Surface_NN Downregulation_NN of_IN Major_JJ Histocompatibility_NN Complex_NP Class_NP I_NP ,_, PE-CAM_NP ,_, and_CC ICAM-1_JJ following_VBG De_NP Novo_NP Infection_NP of_IN Endothelial_NP Cells_NP with_IN Kaposi_NP 's_POS Sarcoma-Associated_NP Herpesvirus_NP Under_IN selective_JJ pressure_NN from_IN host_NN cytotoxic_JJ T_NN lymphocytes_NNS ,_, many_JJ viruses_NNS have_VBP evolved_VBN to_TO downregulate_VB major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) class_NN I_PP and/or_CC T-cell_NN costimulatory_NN molecules_NNS from_IN the_DT surface_NN of_IN infected_JJ cells_NNS ._SENT Kaposi_NP 's_POS sarcoma-associated_JJ herpesvirus_NN (_( KSHV_NP )_) encodes_VBZ two_CD proteins_NNS ,_, MIR-1_NP and_CC MIR-2_NP ,_, that_WDT serve_VBP this_DT function_NN during_IN lytic_JJ replication_NN ._SENT In_IN vivo_JJ ,_, however_RB ,_, KSHV_NP exists_VBZ in_IN a_DT predominantly_RB latent_JJ state_NN ,_, with_IN less_JJR than_IN 5_CD %_NN of_IN infected_JJ cells_NNS expressing_VBG discernible_JJ lytic_JJ gene_NN products_NNS ._SENT Thus_RB ,_, mechanisms_NNS of_IN immune_JJ evasion_NN that_WDT depend_VBP on_IN genes_NNS expressed_VBN only_RB during_IN lytic_JJ replication_NN are_VBP unlikely_JJ to_TO be_VB active_JJ in_IN most_RBS KSHV-infected_JJ cells_NNS ._SENT As_IN a_DT result_NN ,_, we_PP searched_VBD for_IN evidence_NN of_IN similar_JJ defensive_JJ strategies_NNS extant_JJ during_IN latency_NN ,_, employing_VBG culture_NN systems_NNS that_WDT strongly_RB favor_VBP latent_JJ KSHV_NP infection_NN ._SENT We_PP measured_VBD cell_NN surface_NN levels_NNS of_IN immunomodulatory_JJ proteins_NNS on_IN both_DT primary_JJ dermal_JJ microvascular_JJ endothelial_JJ cells_NNS (_( pDMVEC_NN )_) infected_VBN through_IN coculture_NN with_IN induced_VBN primary_JJ effusion_NN lymphoma_NN cells_NNS and_CC telomerase-immortalized_VBD DMVEC_NP infected_VBD directly_RB with_IN cell-free_JJ virus_NN ._SENT Employing_VBG a_DT panel_NN of_IN antibodies_NNS against_IN several_JJ endothelial_JJ cell_NN surface_NN proteins_NNS ,_, we_PP show_VBP that_IN de_NP novo_NP infection_NN with_IN KSHV_NP leads_VBZ to_TO the_DT downregulation_NN of_IN MHC_NP class_NN I_PP ,_, CD31_NP (_( PE-CAM_NP )_) ,_, and_CC CD54_NP (_( ICAM-I_NP )_) but_CC not_RB CD58_NP (_( LFA-3_NP )_) or_CC CD95_NP (_( Fas_NP )_) ._SENT Furthermore_RB ,_, flow_NN cytometry_NN with_IN a_DT fluorescently_RB labeled_VBN monoclonal_NN antibody_NN to_TO the_DT latency-associated_JJ nuclear_JJ antigen_NN (_( LANA_NP )_) revealed_VBD that_IN downregulation_NN occurred_VBD predominantly_RB on_IN KSHV-infected_NP (_( LANA-positive_NP )_) cells_NNS ._SENT Although_IN the_DT vast_JJ majority_NN of_IN infected_JJ cells_NNS displayed_VBD this_DT downregulation_NN ,_, less_JJR than_IN 1_CD %_NN expressed_VBD either_DT immediate-early_JJ or_CC late_JJ lytic_JJ proteins_NNS detectable_JJ by_IN immunofluorescence_NN ._SENT Together_RB ,_, these_DT results_NNS suggest_VBP that_IN downregulation_NN of_IN immunomodulatory_JJ proteins_NNS on_IN the_DT surface_NN of_IN target_NN cells_NNS may_MD represent_VB a_DT constitutive_JJ mode_NN of_IN immune_JJ evasion_NN employed_VBN by_IN KSHV_NP following_VBG de_NP novo_NP infection_NN ._SENT Herpesviruses_NNS constitute_VBP a_DT family_NN of_IN human_JJ pathogens_NNS that_WDT persist_VBP indefinitely_RB in_IN the_DT host_NN organism_NN and_CC often_RB contribute_VB to_TO a_DT variety_NN of_IN disease_NN states_NNS ._SENT Viral_JJ persistence_NN depends_VBZ on_IN the_DT ability_NN of_IN herpesviruses_NNS to_TO establish_VB a_DT latent_JJ infection_NN within_IN cells_NNS ._SENT This_DT process_NN requires_VBZ the_DT successful_JJ evasion_NN of_IN host_NN immune_JJ defenses_NNS ,_, which_WDT usually_RB includes_VBZ the_DT restricted_JJ expression_NN of_IN viral_JJ genes_NNS during_IN latency_NN ._SENT Although_IN such_JJ restriction_NN lowers_VBZ their_PP$ overall_JJ antigenic_JJ profile_NN ,_, herpesviruses_NNS must_MD employ_VB additional_JJ mechanisms_NNS to_TO ensure_VB prolonged_JJ protection_NN from_IN host_NN immune_JJ responses_NNS ._SENT One_CD such_JJ mechanism_NN involves_VBZ the_DT downregulation_NN of_IN immunoregulatory_JJ proteins_NNS ,_, such_JJ as_IN major_JJ histocompatibility_NN complex_NN (_( MHC_NP )_) class_NN I_PP ,_, from_IN the_DT surface_NN of_IN infected_JJ cells_NNS ._SENT This_DT serves_VBZ to_TO limit_VB their_PP$ recognition_NN by_IN cytotoxic_JJ T_NN lymphocytes_NNS (_( CTLs_NP )_) and_CC dampen_VB the_DT inflammatory_JJ response_NN to_TO viral_JJ infection_NN ._SENT Examples_NNS of_IN human_JJ herpesvirus_NN proteins_NNS that_WDT perform_VBP this_DT function_NN include_VBP the_DT ICP47_JJ protein_NN of_IN herpes_NN simplex_NN virus_NN 1_CD ,_, the_DT interleukin-10_JJ protein_NN of_IN Epstein-Barr_NP virus_NN ,_, and_CC the_DT US2_NP ,_, US3_NP ,_, US6_NP ,_, and_CC US11_JJ proteins_NNS of_IN human_JJ cytomegalovirus_NN ._SENT Kaposi_NP 's_POS sarcoma-associated_JJ herpesvirus_NN (_( KSHV_NP )_) is_VBZ a_DT recently_RB discovered_VBN member_NN of_IN the_DT gamma_NN (_( lymphotropic_JJ )_) subfamily_NN of_IN herpesviruses_NNS and_CC is_VBZ responsible_JJ for_IN several_JJ distinct_JJ diseases_NNS in_IN humans_NNS ,_, including_VBG Kaposi_NP 's_POS sarcoma_NN (_( KS_NP )_) ,_, primary_JJ effusion_NN lymphoma_NN (_( PEL_NP )_) ,_, and_CC multicentric_JJ Castleman_NP 's_POS disease_NN ._SENT While_IN pathologically_RB diverse_JJ ,_, these_DT disorders_NNS are_VBP all_RB associated_VBN with_IN an_DT immunocompromised_JJ state_NN and_CC pose_VB a_DT significant_JJ threat_NN to_TO human_JJ immunodeficiency_NN virus-infected_JJ individuals_NNS and_CC solid-organ_NN transplant_NN recipients_NNS worldwide_RB ._SENT In_IN contrast_NN ,_, KSHV_NP infection_NN in_IN healthy_JJ patients_NNS is_VBZ usually_RB asymptomatic_JJ ._SENT In_IN all_DT infected_JJ individuals_NNS ,_, KSHV_NP elicits_VBZ a_DT humoral_JJ and_CC cellular_JJ host_NN immune_JJ response_NN directed_VBN against_IN both_DT lytic_JJ and_CC latent_JJ proteins_NNS of_IN the_DT virus_NN ,_, yet_RB this_DT response_NN ,_, even_RB in_IN healthy_JJ persons_NNS ,_, is_VBZ unable_JJ to_TO eradicate_VB KSHV_NP from_IN the_DT body_NN ._SENT This_DT suggests_VBZ that_IN KSHV_NP ,_, like_IN other_JJ human_JJ herpesviruses_NNS ,_, possesses_VBZ the_DT ability_NN to_TO evade_VB immune_JJ responses_NNS during_IN infection_NN ._SENT Recent_JJ studies_NNS have_VBP identified_VBN several_JJ KSHV_NP lytic_JJ proteins_NNS that_WDT exert_VBP potential_JJ immunoregulatory_JJ roles_NNS during_IN lytic_JJ replication_NN ._SENT These_DT include_VBP inhibition_NN of_IN apoptosis_NN by_IN viral_JJ Bcl-2_NP and_CC open_JJ reading_VBG frame_NN (_( ORF_NP )_) K7_NP ,_, complement_NN deregulation_NN by_IN ORF_NP 4_CD ,_, Th2-type_NP polarization_NN by_IN viral_JJ MIP-II_NP ,_, and_CC inhibition_NN of_IN the_DT interferon_NN antiviral_JJ response_NN by_IN viral_JJ interferon_NN response_NN factor_NN 1_CD (_( vIRF-1_NN )_) ,_, vIRF-3_NN ,_, and_CC viral_JJ interleukin-6_NN ._SENT Furthermore_RB ,_, KSHV_NP also_RB encodes_VBZ two_CD immediate-early_JJ proteins_NNS ,_, MIR-1_NP (_( encoded_VBN by_IN ORF_NP K3_NP )_) and_CC MIR-2_NP (_( encoded_VBN by_IN ORF_NP K5_NP )_) ,_, that_WDT downregulate_VBP immunoregulatory_JJ proteins_NNS such_JJ as_IN MHC_NP class_NN I_PP and_CC ICAM-1_NP from_IN the_DT surface_NN of_IN cells_NNS to_TO limit_VB their_PP$ recognition_NN by_IN immune_JJ cells_NNS (_( 14_CD ,_, 15_CD ,_, 26-28_CD ,_, 61_CD )_) ._SENT KSHV_NP ,_, however_RB ,_, most_RBS often_RB follows_VBZ the_DT general_JJ paradigm_NN of_IN gammaherpesvirus_NN infection_NN ,_, namely_RB a_DT primarily_RB latent_JJ phase_NN of_IN infection_NN marked_VBN by_IN a_DT highly_RB restricted_VBN pattern_NN of_IN viral_JJ gene_NN expression_NN ._SENT The_DT prevalence_NN of_IN KSHV-infected_NP cells_NNS undergoing_VBG lytic_JJ (_( productive_JJ )_) infection_NN both_CC in_IN vitro_NN and_CC in_IN vivo_RB is_VBZ typically_RB low_JJ (_( 1_CD to_TO 5_CD %_NN )_) ,_, with_IN the_DT remaining_VBG infected_JJ cells_NNS harboring_VBG the_DT virus_NN in_IN its_PP$ latent_JJ form_NN ._SENT Thus_RB ,_, mechanisms_NNS of_IN immune_JJ evasion_NN contingent_NN upon_IN genes_NNS expressed_VBN solely_RB during_IN the_DT lytic_JJ cycle_NN would_MD protect_VB only_RB a_DT small_JJ fraction_NN of_IN KSHV-infected_NP cells_NNS ._SENT It_PP follows_VBZ ,_, therefore_RB ,_, that_IN KSHV_NP may_MD additionally_RB require_VB mechanisms_NNS of_IN evasion_NN that_WDT are_VBP active_JJ during_IN latency_NN ._SENT Several_JJ KSHV_NP latent_JJ proteins_NNS have_VBP likewise_RB been_VBN implicated_VBN in_IN viral_JJ immune_JJ evasion_NN ._SENT These_DT include_VBP disruption_NN of_IN p53_NN by_IN latency-associated_JJ nuclear_JJ antigen_NN (_( LANA_NP )_) and_CC LANA2_NP ,_, inhibition_NN of_IN apoptosis_NN by_IN viral_JJ FLIP_NP ,_, downregulation_NN of_IN the_DT B-cell_NN receptor_NN by_IN ORF_NP K1_NP ,_, and_CC deregulation_NN of_IN the_DT interferon_NN response_NN by_IN vIRF-II_NNS ._SENT Additionally_RB ,_, work_NN by_IN Brander_NP et_FW al._FW has_VBZ shown_VBN that_IN KSHV-infected_NP PEL_NP cells_NNS express_VBP lower_JJR levels_NNS of_IN MHC_NP class_NN I_PP and_CC possess_VB increased_VBN resistance_NN to_TO CTLs_NNS compared_VBN with_IN Epstein-Barr_NP virus-infected_JJ or_CC primary_JJ B_NN cells_NNS ._SENT However_RB ,_, the_DT relevance_NN of_IN these_DT findings_NNS to_TO de_NP novo_NN infection_NN of_IN endothelial_JJ cells_NNS with_IN intact_JJ KSHV_NP remains_VBZ unknown_JJ ._SENT Therefore_RB ,_, we_PP investigated_VBD the_DT potential_JJ viral_JJ immune_JJ evasion_NN strategies_NNS of_IN KSHV_NP in_IN two_CD endothelial_JJ cell_NN culture_NN systems_NNS that_WDT strongly_RB favor_VBP latent_JJ infection_NN with_IN KSHV_NP ._SENT Specifically_RB ,_, we_PP tested_VBD telomerase-immortalized_JJ dermal_JJ microvascular_JJ endothelial_JJ cells_NNS (_( DMVEC_NP )_) infected_VBD with_IN concentrated_JJ virus_NN and_CC primary_JJ DMVEC_NP (_( pDMVEC_NN )_) infected_VBN via_IN coculture_NN with_IN induced_VBN BCBL-1_JJ cells_NNS ,_, a_DT PEL_NP line_NN harboring_VBG KSHV_NP ._SENT With_IN a_DT panel_NN of_IN antibodies_NNS against_IN numerous_JJ endothelial_JJ cell_NN surface_NN proteins_NNS ,_, we_PP examined_VBD these_DT immortalized_VBN and_CC primary_JJ cells_NNS for_IN signs_NNS of_IN immune_JJ modulation_NN following_VBG de_NP novo_NN infection_NN with_IN KSHV_NP ._SENT Cell_NN culture_NN ._SENT |_SYM BCBL-1_NP and_CC BJAB_NP cells_NNS were_VBD grown_VBN in_IN RPMI_NP 1640_CD medium_NN (_( Gibco_NP ,_, Rockville_NP ,_, Md._NP )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN ,_, 10_CD mM_NP HEPES_NP (_( pH_NN 7.5_CD )_) ,_, 100_CD U_NN of_IN penicillin_NN per_IN ml_NN ,_, 100_CD mug_NN of_IN streptomycin_NN per_IN ml_NN ,_, 2_CD mM_NP l-glutamine_NN ,_, 0.05_CD mM_NP beta-mercaptoethanol_NN ,_, and_CC 0.02_CD %_NN (_( wt/vol_NN )_) sodium_NN bicarbonate_NN ._SENT Cells_NNS were_VBD maintained_VBN at_IN 2.5_CD x_NN 105_CD to_TO 8.0_CD x_SYM 105/ml_NN and_CC were_VBD used_VBN for_IN up_IN to_TO 2_CD months_NNS after_IN the_DT thaw_NN date_NN ._SENT pDMVEC_NN were_VBD obtained_VBN from_IN Clonetics_NP Corporation_NP (_( Walkersville_NP ,_, Md._NP )_) at_IN low_JJ passage_NN and_CC grown_VBN in_IN EGM-2_NP MV_NP medium_NN (_( Clonetics_NP )_) with_IN 50_CD U_NN of_IN penicillin_NN per_IN ml_NN and_CC 50_CD mug_NN of_IN streptomycin_NN per_IN ml_NN substituted_VBN for_IN amphotericin_NP B_NP and_CC gentamicin_NN ._SENT Creation_NN of_IN T4_NP TIME_NN cells_NNS ._SENT |_SYM Telomerase-immortalized_JJ microvascular_JJ endothelial_JJ (_( T4_NP TIME_NN )_) cells_NNS were_VBD generated_VBN from_IN pDMVEC_NN with_IN the_DT stable_JJ incorporation_NN of_IN the_DT human_JJ telomerase_NN gene_NN (_( hTERT_NN )_) by_IN retroviral_JJ transduction_NN ._SENT Briefly_RB ,_, the_DT pBABE_NP retroviral_JJ plasmid_NN containing_VBG the_DT hTERT_NN gene_NN (_( a_DT gift_NN from_IN R._NP Weinberg_NP )_) was_VBD packaged_VBN into_IN a_DT Moloney_NP murine_JJ leukemia_NN virus_NN pseudo_JJ typed_VBN with_IN the_DT vesicular_JJ stomatitis_NN virus_NN glycoprotein_NN G._NP This_DT virus_NN was_VBD then_RB transduced_VBN into_IN pDMVEC_NN by_IN spinfection_NN for_IN 2_CD h_NN at_IN 1,000_CD x_NN g_NN ,_, and_CC stable_JJ clones_NNS were_VBD selected_VBN in_IN the_DT presence_NN of_IN 0.5_CD mug_NN of_IN puromycin_NN per_IN ml_NN for_IN 1_CD month_NN ._SENT hTERT_NN expression_NN was_VBD then_RB confirmed_VBN with_IN the_DT Trapeze_JJ telomerase_NN detection_NN kit_NN (_( Intergen_NP ,_, Manhattan_NP N.Y._NP )_) ._SENT One_CD of_IN the_DT resultant_JJ clones_NNS ,_, T4_NP ,_, expressed_VBD high_JJ levels_NNS of_IN telomerase_NN ,_, as_RB determined_VBN by_IN telomerase_NN repeat_NN amplification_NN analysis_NN and_CC has_VBZ survived_VBN ,_, to_TO date_VB ,_, over_IN 80_CD passages_NNS without_IN detectable_JJ changes_NNS in_IN morphology_NN ,_, growth_NN rate_NN ,_, or_CC susceptibility_NN to_TO infection_NN with_IN KSHV_NP compared_VBN with_IN early-passage_NP T4_NP TIME_NN cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Coculture_NN infection_NN of_IN pDMVEC_NN cells_NNS with_IN KSHV_NP ._SENT |_SYM pDMVEC_NN at_IN early_JJ passage_NN (_( <15_JJ passages_NNS )_) were_VBD infected_VBN by_IN coculture_NN with_IN the_DT primary_JJ effusion_NN lymphoma_NN cell_NN line_NN BCBL-1_NP ,_, based_VBN on_IN methods_NNS described_VBN by_IN Sakurada_NP et_FW al._FW ._SENT Briefly_RB ,_, BCBL-1_NP cells_NNS were_VBD induced_VBN with_IN a_DT 12-h_NP exposure_NN to_TO 20_CD ng_NNS of_IN O-tetradecanoyl_NP phorbol_NN 13-acetate_JJ per_IN ml_NN and_CC 300_CD muM_NN sodium_NN butyrate_NN and_CC ,_, after_IN 3_CD days_NNS ,_, cocultured_VBN directly_RB with_IN pDMVEC_NN at_IN various_JJ ratios_NNS for_IN 12_CD h_NN in_IN RPMI_NP 1640_CD medium_NN supplemented_VBN with_IN 10_CD %_NN fetal_JJ bovine_JJ serum_NN and_CC 100_CD mug_NN of_IN endothelial_JJ cell_NN growth_NN supplement_NN per_IN ml_NN (_( BD_NP Pharmingen_NP ,_, San_NP Jose_NP ,_, Calif._NP )_) ._SENT The_DT pDMVEC_NN were_VBD then_RB washed_VBN vigorously_RB to_TO remove_VB the_DT BCBL-1_JJ cells_NNS and_CC cultured_VBN for_IN an_DT additional_JJ day_NN in_IN EGM-2_NP endothelial_JJ cell_NN medium_NN lacking_VBG hydrocortisone_NN ._SENT We_PP found_VBD that_IN low_JJ levels_NNS of_IN hydrocortisone_NN ,_, normally_RB present_JJ in_IN EGM-2_NP endothelial_JJ growth_NN medium_NN ,_, led_VBN to_TO a_DT modest_JJ two-_NN to_TO threefold_JJ induction_NN of_IN immediate-early_JJ lytic_JJ protein_NN expression_NN in_IN the_DT immunofluorescence_NN assay_NN (_( data_NNS not_RB shown_VBN )_) ._SENT As_IN a_DT result_NN ,_, we_PP eliminated_VBD hydrocortisone_NN from_IN the_DT growth_NN medium_NN in_IN all_DT short-term_JJ experiments_NNS to_TO minimize_VB the_DT levels_NNS of_IN spontaneous_JJ lytic_JJ reactivation_NN ._SENT For_IN controls_NNS ,_, pDMVEC_NN were_VBD cocultured_VBN with_IN uninduced_JJ BCBL-1_JJ cells_NNS or_CC BCBL-1_JJ cells_NNS induced_VBN in_IN the_DT presence_NN of_IN 0.5_CD mM_NP phosphonoformic_JJ acid_NN (_( Sigma_NP Aldrich_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) ._SENT Cell-free_JJ virus_NN infection_NN of_IN T4_NP TIME_NN cells_NNS ._SENT |_SYM BCBL-1_NP cells_NNS were_VBD induced_VBN as_IN described_VBN above_IN ,_, and_CC virus_NN was_VBD collected_VBN from_IN the_DT supernatant_JJ on_IN the_DT sixth_JJ day_NN after_IN induction_NN by_IN centrifugation_NN at_IN 13,000_CD x_NN g_NN for_IN 3_CD h._NN The_DT viral_JJ pellet_NN was_VBD resuspended_VBN at_IN 100th_JJ the_DT original_JJ volume_NN in_IN EGM-2_NP MV_NP culture_NN medium_NN lacking_VBG hydrocortisone_NN ,_, and_CC aliquots_NNS were_VBD frozen_VBN at_IN -80C_NN ._SENT A_DT small_JJ aliquot_NN of_IN concentrated_JJ virus_NN was_VBD used_VBN to_TO determine_VB the_DT number_NN of_IN viral_JJ genome_NN equivalents_NNS by_IN Southern_JJ blot_NN analysis_NN with_IN a_DT fluorescently_RB labeled_VBN single-stranded_JJ KSHV_NP DNA_NN probe_NN complementary_JJ to_TO ORF_NP 73_CD (_( Random_NP Primer_NP DNA_NP chemiluminescence_NN kit_NN ;_: New_NP England_NP Nuclear_NP ,_, Boston_NP ,_, Mass._NP )_) ._SENT Approximately_RB 5,000_CD viral_JJ genome_NN equivalents_NNS per_IN endothelial_JJ cell_NN were_VBD then_RB used_VBN to_TO infect_VB T4_NP TIME_NN cells_NNS in_IN the_DT presence_NN of_IN 8_CD mug_NN of_IN Polybrene_NP per_IN ml_NP (_( Sigma_NP Aldrich_NP )_) for_IN 2_CD h._NP Hydrocortisone_NP was_VBD omitted_VBN from_IN the_DT culture_NN medium_NN 24_CD h_NN before_IN addition_NN of_IN the_DT virus_NN ._SENT For_IN controls_NNS ,_, a_DT sister_JJ plate_NN was_VBD infected_VBN with_IN an_DT equivalent_JJ amount_NN of_IN virus_NN that_WDT was_VBD first_JJ heat_NN inactivated_VBN for_IN 30_CD min_NN at_IN 65C_JJ or_CC UV-inactivated_JJ at_IN 40_CD W_NN for_IN 60_CD min_NN with_IN 254-nm_JJ UV_NP light_NN ._SENT Cells_NNS were_VBD then_RB washed_VBN to_TO remove_VB the_DT Polybrene_NP and_CC incubated_VBN for_IN 2_CD days_NNS in_IN fresh_JJ EGM-2_JJ medium_NN lacking_VBG hydrocortisone_NN ._SENT Flow_NN cytometry_NN ._SENT |_SYM pDMVEC_NP and_CC T4_NP TIME_NN cells_NNS were_VBD infected_VBN with_IN KSHV_NP as_RB described_VBD above_IN and_CC harvested_VBN for_IN flow_NN cytometry_NN at_IN the_DT indicated_JJ times_NNS ._SENT Cells_NNS were_VBD detached_VBN from_IN the_DT plate_NN with_IN a_DT 0.25_CD %_NN trypsin-EDTA_NN solution_NN (_( Clonetics_NP )_) ,_, and_CC 0.5_CD x_SYM 106_CD cells_NNS per_IN sample_NN were_VBD then_RB transferred_VBN to_TO a_DT 96-well_NN plate_NN after_IN assessing_VBG cell_NN count_NN and_CC viability_NN by_IN trypan_JJ blue_JJ exclusion_NN ._SENT For_IN surface_NN staining_VBG ,_, samples_NNS were_VBD washed_VBN twice_RB with_IN 1x_NP PBSA_NP (_( 1x_NP phosphate-buffered_JJ saline_NN [_SYM PBS_NP ]_SYM with_IN 0.09_CD %_NN sodium_NN azide_NN )_) and_CC blocked_VBN for_IN 30_CD min_NN with_IN antibody_NN staining_VBG buffer_NN (_( 3_CD %_NN fetal_JJ bovine_JJ serum_NN in_IN PBSA_NP )_) ._SENT Cell_NN surface_NN staining_VBG was_VBD then_RB carried_VBN out_RP for_IN 1_CD h_NN at_IN 4C_JJ in_IN the_DT dark_NN ._SENT All_DT cell_NN surface_NN antibodies_NNS and_CC isotype_NN controls_NNS were_VBD obtained_VBN from_IN BD_NP Pharmingen_NP and_CC used_VBN at_IN the_DT recommended_JJ dilution_NN of_IN 0.25_CD mug_NN of_IN antibody/106_JJ cells_NNS in_IN antibody_NN staining_VBG solution_NN ._SENT Apoptotic_JJ cells_NNS were_VBD identified_VBN with_IN the_DT annexin_NN V_CD fluorescein_NN isothiocyanate_NN apoptosis_NN detection_NN kit_NN as_IN described_VBN by_IN the_DT manufacturer_NN (_( BD_NP Pharmingen_NP )_) ._SENT Cells_NNS were_VBD then_RB washed_VBN twice_RB with_IN cold_JJ 1x_NP PBSA_NP and_CC permeabilized_VBN for_IN nuclear_JJ staining_VBG with_IN the_DT paraformaldehyde-saponin-based_JJ bromodeoxyuridine_NN Fix/Perm_NN kit_NN from_IN BD_NP Pharmingen_NP as_RB described_VBD by_IN the_DT manufacturer_NN ._SENT Nuclear_JJ staining_VBG to_TO identify_VB KSHV-infected_NP cells_NNS was_VBD performed_VBN with_IN a_DT rat_NN monoclonal_NN antibody_NN to_TO the_DT KSHV_NP LANA_NP protein_NN (_( Applied_NP Biosciences_NP Inc._NP ,_, Columbia_NP ,_, Md._NP )_) conjugated_VBD to_TO the_DT fluorochrome_NN Alexa_NP 488_CD per_IN the_DT manufacturer_NN 's_POS protocol_NN (_( Molecular_NP Probes_NP ,_, Eugene_NP ,_, Oreg_NP ._SENT )_) and_CC used_VBN at_IN a_DT 1:1,000_CD dilution_NN in_IN BD_NP Pharmingen_NP Perm/Wash_NP buffer_NN supplemented_VBD with_IN 3_CD %_NN fetal_JJ bovine_JJ serum_NN ._SENT Flow_NN cytometry_NN was_VBD performed_VBN with_IN a_DT FACSCalibur_NP flow_NN cytometer_NN and_CC analyzed_VBD with_IN Cell_NP Quest_NP Pro_NP software_NN (_( Becton_NP Dickinson_NP ,_, Bedford_NP ,_, Mass._NP )_) ._SENT Prior_RB to_TO analysis_NN ,_, all_DT samples_NNS were_VBD gated_VBN by_IN forward_JJ and_CC side_JJ scatter_NN to_TO eliminate_VB dead_JJ cells_NNS ._SENT Immunofluorescence_NN ._SENT |_SYM T4_NP TIME_NN cells_NNS and_CC pDMVEC_NN (_( with_IN and_CC without_IN KSHV_NP )_) were_VBD grown_VBN overnight_RB on_IN Becton_NP Dickinson_NP eight-well_NP culture_NN slides_NNS coated_VBN with_IN fibronectin_NN ._SENT The_DT slides_NNS were_VBD then_RB fixed_VBN in_IN 95_CD %_NN ethanol-5_NN %_NN acetic_JJ acid_NN for_IN 10_CD min_NN at_IN room_NN temperature_NN and_CC permeabilized_VBN in_IN PBS_NP with_IN 0.5_CD %_NN Triton_NP X-100_NP for_IN 20_CD min_NN at_IN room_NN temperature_NN as_IN described_VBN by_IN Moses_NN et_FW al._FW ._SENT Nonspecific_JJ binding_NN was_VBD blocked_VBN by_IN incubating_VBG the_DT cells_NNS with_IN 10_CD %_NN goat_NN serum_NN supplemented_VBN with_IN 1_CD %_NN glycine_NN and_CC 3_CD %_NN bovine_JJ serum_NN albumin_NN and_CC then_RB with_IN the_DT appropriate_JJ primary_JJ antibody_NN diluted_VBN in_IN blocking_VBG buffer_NN for_IN 60_CD min_NN ._SENT To_TO determine_VB the_DT extent_NN of_IN KSHV_NP infection_NN ,_, cells_NNS were_VBD assayed_VBN for_IN LANA_NP expression_NN with_IN Alexa_NP 488-conjugated_JJ monoclonal_NN antibody_NN to_TO LANA_NP at_IN a_DT 1:1,000_CD dilution_NN ._SENT Rabbit_NN polyclonal_JJ antibodies_NNS to_TO RTA_NP (_( ORF_NP 50_CD )_) ,_, (_( a_DT gift_NN from_IN D._NP Lukac_NP )_) ,_, ORF_NP 45_CD (_( a_DT gift_NN from_IN Y._NP Yuan_NP )_) ,_, MIR-1_NP (_( ORF_NP K3_NP )_) and_CC MIR-2_NP (_( ORF_NP K5_NP )_) (_( both_CC gifts_NNS from_IN G._NP Hayward_NP )_) ,_, MCP_NP (_( ORF_NP 25_CD )_) and_CC SCAF_NP (_( ORF_NP 17.5_CD )_) were_VBD all_RB used_VBN at_IN 1:500_CD except_IN MIR-2_NP ,_, which_WDT was_VBD used_VBN at_IN 1:1,000_CD ._SENT Following_VBG staining_VBG with_IN primary_JJ antibodies_NNS ,_, cells_NNS were_VBD washed_VBN twice_RB with_IN 1x_NP PBS_NP and_CC then_RB incubated_VBN with_IN goat_NN anti-rabbit_NN immunoglobulin_NN conjugated_VBN to_TO Texas_NP Red_NP (_( Jackson_NP Labs_NP ,_, West_NP Grove_NP ._SENT Pa._NP )_) diluted_VBD 1:150_CD for_IN 60_CD min_NN in_IN the_DT dark_NN ._SENT Cells_NNS were_VBD then_RB washed_VBN twice_RB with_IN 1x_NP PBS_NP and_CC subsequently_RB stained_VBN with_IN 0.5_CD mug_NN of_IN 4',6'-diamidino-2-phenylindole_JJ (_( DAPI_NP )_) (_( Sigma_NP )_) per_IN ml_NN in_IN 180_CD mM_NP Tris_NP (_( pH_NN 7.5_CD )_) for_IN 30_CD min_NN at_IN 4C_JJ in_IN the_DT dark_NN ._SENT The_DT slide_NN was_VBD then_RB coated_VBN with_IN Antifade_NN mounting_VBG solution_NN (_( Biomeda_NP ,_, Foster_NP City_NP ,_, Calif._NP )_) and_CC sealed_VBN with_IN a_DT coverslip_NN ._SENT Paracrine_NN experiments_NNS ._SENT |_SYM Medium_NN was_VBD harvested_VBN from_IN T4_NP TIME_NN cells_NNS 48_CD h_NN after_IN infection_NN with_IN cell-free_JJ virus_NN (_( as_RB described_VBN above_IN )_) ._SENT The_DT medium_NN was_VBD cleared_VBN of_IN cell_NN debris_NN and_CC viral_JJ particles_NNS by_IN ultracentrifugation_NN at_IN 75,000_CD x_NN g_NN for_IN 30_CD min_NN in_IN an_DT SW-55Ti_NP rotor_NN (_( Sorvall_NP ,_, Newtown_NP ,_, Conn._NP )_) ._SENT Naive_JJ T4_NP TIME_NN cells_NNS were_VBD then_RB incubated_VBN with_IN the_DT virus-free_JJ supernatant_JJ for_IN 48_CD h_NN and_CC prepared_VBN for_IN flow_NN cytometry_NN as_RB described_VBD above_IN ._SENT Naive_JJ T4_NP TIME_NN cells_NNS incubated_VBN with_IN medium_NN from_IN mock-infected_JJ T4_NP TIME_NN cells_NNS prepared_VBD similarly_RB served_VBN as_IN controls_NNS ._SENT KSHV_NP infection_NN of_IN telomerase-immortalized_JJ endothelial_JJ cells_NNS ._SENT |_SYM To_TO investigate_VB potential_JJ KSHV-specific_NP immune_JJ evasion_NN strategies_NNS ,_, we_PP assessed_VBD changes_NNS in_IN the_DT expression_NN of_IN specific_JJ cell_NN surface_NN proteins_NNS following_VBG de_NP novo_NN infection_NN of_IN endothelial_JJ cells_NNS with_IN KSHV_NP ._SENT We_PP focused_VBD our_PP$ initial_JJ efforts_NNS on_IN DMVEC_NP because_IN they_PP represent_VBP a_DT probable_JJ target_NN cell_NN of_IN KSHV_NP within_IN Kaposi_NP 's_POS sarcoma_NN lesions_NNS in_IN vivo_RB ._SENT Previous_JJ attempts_NNS at_IN infecting_VBG similar_JJ cells_NNS with_IN KSHV_NP ,_, however_RB ,_, have_VBP resulted_VBN in_IN initial_JJ infection_NN rates_NNS of_IN less_JJR than_IN 5_CD %_NN ._SENT Therefore_RB ,_, we_PP took_VBD advantage_NN of_IN recent_JJ findings_NNS indicating_VBG that_DT human_JJ pDMVEC_NN first_RB immortalized_VBN with_IN the_DT human_JJ telomerase_NN gene_NN (_( hTERT_NN )_) support_VBP higher_JJR rates_NNS of_IN infection_NN with_IN concentrated_JJ KSHV_NP ._SENT We_PP created_VBD hTERT-immortalized_JJ microvascular_JJ endothelial_JJ cells_NNS (_( TIME_NN cells_NNS )_) through_IN the_DT retroviral_JJ insertion_NN of_IN hTERT_NN into_IN pDMVEC_NN and_CC the_DT subsequent_JJ selection_NN of_IN antibiotic-resistant_JJ colonies_NNS (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT Infection_NN of_IN one_CD of_IN the_DT resultant_JJ clones_NNS ,_, T4_NP ,_, with_IN the_DT concentrated_JJ viral_JJ supernatant_JJ from_IN the_DT KSHV-infected_NP PEL_NP line_NN BCBL-1_NP resulted_VBD in_IN a_DT dramatic_JJ morphological_JJ change_NN in_IN many_JJ of_IN the_DT target_NN endothelial_JJ cells_NNS to_TO a_DT spindle-like_JJ phenotype_NN within_IN 24_CD h_NN ._SENT This_DT change_NN is_VBZ characteristic_JJ of_IN KSHV_NP infection_NN of_IN endothelial_JJ cells_NNS and_CC coincided_VBD closely_RB with_IN the_DT onset_NN of_IN latent_JJ gene_NN expression_NN ,_, as_RB evidenced_VBN by_IN the_DT detection_NN of_IN LANA_NP by_IN the_DT immunofluorescence_NN assay_NN ._SENT In_IN contrast_NN ,_, incubation_NN of_IN T4_NP cells_NNS with_IN either_DT UV-treated_JJ (_( not_RB shown_VBN )_) or_CC heat-inactivated_NP KSHV_NP caused_VBD neither_DT LANA_NP staining_VBG nor_CC morphological_JJ changes_NNS associated_VBN with_IN infection_NN (_( Fig._NN and_CC D_NN )_) ._SENT The_DT proportion_NN of_IN cells_NNS infected_VBN with_IN KSHV_NP correlated_VBD with_IN the_DT amount_NN of_IN input_NN virus_NN ,_, determined_VBN by_IN viral_JJ genome_NN copy_NN number_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT However_RB ,_, with_IN viral_JJ concentrations_NNS sufficient_JJ to_TO generate_VB 100_CD %_NN infection_NN of_IN all_DT of_IN the_DT target_NN cells_NNS ,_, we_PP often_RB observed_VBD excessive_JJ cell_NN death_NN ._SENT To_TO avoid_VB this_DT issue_NN ,_, we_PP optimized_VBD the_DT initial_JJ infection_NN level_NN in_IN most_JJS experiments_NNS to_TO approximately_RB 50_CD %_NN by_IN maintaining_VBG a_DT constant_JJ ratio_NN of_IN KSHV_NP genome_NN copy_NN number_NN to_TO target_VB cell_NN of_IN approximately_RB 5,000:1_CD ._SENT This_DT high_JJ ratio_NN may_MD reflect_VB the_DT small_JJ proportion_NN of_IN DNA-containing_NP particles_NNS that_WDT are_VBP infectious_JJ virions_NNS as_RB well_RB as_IN the_DT relatively_RB low_JJ susceptibility_NN of_IN endothelial_JJ cells_NNS to_TO KSHV_NP infection_NN (_( C._NP Tomescu_NP and_CC D._NP H._NP Kedes_NP ,_, unpublished_JJ observations_NNS )_) ._SENT With_IN initial_JJ infection_NN rates_NNS of_IN approximately_RB 50_CD %_NN ,_, the_DT number_NN of_IN infected_JJ (_( LANA-positive_JJ )_) cells_NNS remained_VBD stable_JJ for_IN several_JJ days_NNS ._SENT However_RB ,_, the_DT proportion_NN of_IN KSHV-infected_NP cells_NNS began_VBD to_TO decrease_VB with_IN continued_JJ culture_NN ._SENT This_DT reduction_NN began_VBD approximately_RB 4_CD days_NNS postinfection_NN ,_, so_RB that_IN by_IN 3_CD weeks_NNS fewer_JJR than_IN 15_CD %_NN of_IN the_DT cells_NNS remained_VBD positive_JJ (_( data_NNS not_RB shown_VBN )_) ._SENT This_DT reduction_NN may_MD reflect_VB either_DT loss_NN of_IN the_DT virus_NN from_IN within_IN infected_JJ endothelial_JJ cells_NNS over_IN time_NN or_CC a_DT growth_NN advantage_NN of_IN uninfected_JJ over_IN infected_JJ cells_NNS within_IN the_DT culture_NN ._SENT As_IN a_DT result_NN ,_, we_PP restricted_VBD most_JJS of_IN our_PP$ analyses_NNS to_TO the_DT first_JJ 72_CD h_NN postinfection_NN ._SENT We_PP next_RB characterized_VBD the_DT frequency_NN of_IN viral_JJ lytic_JJ gene_NN expression_NN among_IN the_DT newly_RB infected_JJ T4_NP TIME_NN cells_NNS ._SENT Lagunoff_NP and_CC colleagues_NNS reported_VBD that_DT incubation_NN of_IN a_DT similarly_RB derived_VBN TIME_NN cell_NN line_NN with_IN KSHV_NP resulted_VBD in_IN predominantly_RB latent_JJ infection_NN ,_, with_IN lytic_JJ protein_NN expression_NN confined_VBN to_TO less_JJR than_IN 1_CD %_NN of_IN infected_JJ cells_NNS ._SENT To_TO explore_VB whether_IN our_PP$ T4_NP TIME_NN cells_NNS displayed_VBD a_DT similar_JJ latent_JJ bias_NN after_IN infection_NN ,_, we_PP assayed_VBD for_IN KSHV_NP lytic_JJ protein_NN expression_NN by_IN immunofluorescence_NN with_IN antibodies_NNS specific_JJ for_IN four_CD immediate-early_JJ lytic_JJ gene_NN products_NNS ,_, ORF_NP 50_CD (_( RTA_NP )_) ,_, ORF_NP 45_CD ,_, K3_NP (_( MIR-1_NP )_) ,_, and_CC K5_NP (_( MIR-2_NP )_) ,_, as_RB well_RB as_IN two_CD late_JJ lytic_JJ gene_NN products_NNS ,_, ORF_NP 17.5_CD (_( SCAF_NP )_) and_CC ORF_NP 25_NP (_( MCP_NP )_) ._SENT We_PP also_RB costained_VBD samples_NNS for_IN latent_JJ protein_NN expression_NN with_IN a_DT monoclonal_NN antibody_NN to_TO LANA_NP to_TO identify_VB the_DT KSHV-infected_NP cells_NNS in_IN the_DT culture_NN ._SENT With_IN this_DT approach_NN ,_, we_PP observed_VBD a_DT relative_JJ paucity_NN of_IN both_DT immediate-early_JJ and_CC late_JJ lytic_JJ protein_NN expression_NN in_IN the_DT great_JJ majority_NN of_IN KSHV-infected_NP (_( LANA-positive_NP )_) cells_NNS (_( Fig._NN ,_, third_JJ and_CC fourth_JJ columns_NNS )_) ._SENT Specifically_RB ,_, immunofluorescence_NN assays_NNS detected_VBD the_DT immediate-early_JJ lytic_JJ proteins_NNS RTA_NP ,_, MIR-1_NP ,_, and_CC MIR-2_NP in_IN only_RB 1_CD %_NN of_IN KSHV-infected_NP T4_NP TIME_NN cells_NNS (_( Fig._NN ,_, fourth_JJ column_NN )_) ._SENT ORF_NN 45_CD antibodies_NNS gave_VBD similar_JJ results_NNS (_( data_NNS not_RB shown_VBN )_) ,_, while_IN even_RB fewer_JJR cells_NNS demonstrated_VBD late_JJ lytic_JJ proteins_NNS such_JJ as_IN SCAF_NP (_( not_RB shown_VBN )_) and_CC MCP_NP (_( Fig._NN ,_, fourth_JJ column_NN )_) ._SENT This_DT last_JJ finding_NN may_MD reflect_VB premature_JJ termination_NN of_IN the_DT lytic_JJ cascade_NN prior_RB to_TO expression_NN of_IN late_JJ lytic_JJ proteins_NNS in_IN the_DT few_JJ cells_NNS undergoing_VBG spontaneous_JJ lytic_JJ reactivation_NN ._SENT Under_IN higher_JJR magnification_NN ,_, reactivity_NN with_IN antibodies_NNS to_TO lytic_JJ proteins_NNS in_IN most_JJS KSHV-infected_NP cells_NNS was_VBD indistinguishable_JJ from_IN background_NN levels_NNS with_IN secondary_JJ antibody_NN alone_RB (_( Fig._NN ,_, third_JJ column_NN )_) despite_IN characteristic_JJ LANA_NP staining_VBG (_( Fig._NN ,_, first_JJ column_NN )_) ._SENT In_IN parallel_JJ assays_NNS ,_, the_DT same_JJ set_NN of_IN lytic_JJ antibodies_NNS reacted_VBN with_IN 10_CD to_TO 15_CD %_NN of_IN similarly_RB induced_VBN BCBL-1_JJ cells_NNS (_( not_RB shown_VBN )_) ,_, reflecting_VBG the_DT higher_JJR levels_NNS of_IN lytic_JJ reactivation_NN that_WDT characterize_VBP this_DT PEL_NP line_NN ._SENT Together_RB ,_, these_DT results_NNS argue_VBP that_IN KSHV_NP infection_NN of_IN T4_NP TIME_NN cells_NNS ,_, in_IN the_DT absence_NN of_IN inducing_VBG agents_NNS ,_, is_VBZ predominantly_RB latent_JJ ._SENT Nevertheless_RB ,_, we_PP cannot_MD rule_VB out_RP the_DT distinct_JJ possibility_NN that_IN low_JJ levels_NNS of_IN lytic_JJ proteins_NNS ,_, expressed_VBN in_IN quantities_NNS below_IN the_DT sensitivity_NN of_IN our_PP$ immunofluorescence_NN assay_NN ,_, are_VBP present_JJ in_IN some_DT cells_NNS following_VBG KSHV_NP infection_NN ._SENT Downregulation_NN of_IN MHC_NP class_NN I_PP ,_, PE-CAM_NP ,_, and_CC ICAM-1_NP after_IN de_NP novo_NP infection_NN of_IN T4_NP TIME_NN cells_NNS with_IN KSHV_NP ._SENT |_SYM To_TO investigate_VB potential_JJ KSHV-specific_NP immune_JJ evasion_NN strategies_NNS that_WDT might_MD arise_VB following_VBG initial_JJ infection_NN ,_, we_PP examined_VBD newly_RB infected_JJ T4_NP TIME_NN cells_NNS with_IN a_DT panel_NN of_IN antibodies_NNS to_TO endothelial_JJ cell_NN surface_NN proteins_NNS involved_VBN in_IN immune_JJ recognition_NN ._SENT This_DT analysis_NN included_VBD monoclonal_NN antibodies_NNS to_TO MHC_NP class_NN I_PP ,_, MHC_NP class_NN II_NP ,_, CD31_NP (_( PE-CAM_NP )_) ,_, CD40_NP ,_, CD54_NP (_( ICAM-1_NP )_) ,_, CD58_NP (_( LFA-3_NP )_) ,_, CD80_NP (_( B7.1_NP )_) ,_, CD86_NP (_( B7.2_NP )_) ,_, and_CC CD95_NP (_( Fas_NP )_) ._SENT While_IN four_CD of_IN these_DT nine_CD proteins_NNS ,_, MHC_NP class_NN II_NP ,_, B7.1_NP ,_, B7.2_NP ,_, and_CC CD40_NP ,_, were_VBD only_RB poorly_RB expressed_VBN on_IN T4_NP TIME_NN cells_NNS ,_, the_DT five_CD remaining_VBG proteins_NNS were_VBD well_RB represented_VBN prior_RB to_TO KSHV_NP infection_NN ._SENT We_PP monitored_VBD the_DT cell_NN surface_NN expression_NN of_IN this_DT set_NN and_CC observed_VBD a_DT significant_JJ downregulation_NN of_IN three_CD of_IN the_DT proteins_NNS shortly_RB after_IN infection_NN ._SENT Included_VBN among_IN these_DT was_VBD MHC_NP class_NN I_PP ,_, which_WDT was_VBD distinctly_RB downregulated_JJ within_IN 48_CD h_NN of_IN KSHV_NP infection_NN ._SENT In_IN contrast_NN ,_, incubation_NN of_IN T4_NP TIME_NN cells_NNS with_IN heat-_NN or_CC UV-inactivated_JJ virus_NN led_VBN to_TO no_DT change_NN in_IN MHC_NP class_NN I_PP levels_NNS compared_VBN with_IN uninfected_JJ ,_, naive_JJ cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT The_DT number_NN of_IN cells_NNS with_IN downregulated_JJ MHC_NP class_NN I_PP varied_VBD proportionally_RB with_IN the_DT amount_NN of_IN input_NN virus_NN and_CC ,_, in_IN turn_NN ,_, with_IN the_DT level_NN of_IN infection_NN as_RB reflected_VBD by_IN LANA_NP reactivity_NN in_IN immunofluorescence_NN assays_NNS (_( not_RB shown_VBN )_) ._SENT Furthermore_RB ,_, flow_NN cytometry_NN of_IN cultures_NNS that_WDT were_VBD approximately_RB 50_CD %_NN infected_VBN (_( LANA_NP positive_NN )_) most_RBS often_RB demonstrated_VBN a_DT widened_VBN distribution_NN of_IN MHC_NP class_NN I_PP signal_VBP rather_RB than_IN a_DT biphasic_JJ curve_NN with_IN two_CD distinct_JJ populations_NNS ,_, indicating_VBG that_IN the_DT extent_NN of_IN downregulation_NN per_IN cell_NN varied_VBN considerably_RB ._SENT Nevertheless_RB ,_, the_DT mean_JJ KSHV-associated_NP reduction_NN in_IN MHC_NP class_NN I_PP ranged_VBD between_IN two_CD and_CC fivefold_RB compared_VBN to_TO mock-infected_JJ control_NN cultures_NNS in_IN four_CD separate_JJ experiments_NNS ._SENT These_DT measurements_NNS ,_, however_RB ,_, represent_VBP a_DT minimal_JJ estimate_NN ,_, since_IN approximately_RB 50_CD %_NN of_IN the_DT cells_NNS in_IN the_DT cultures_NNS were_VBD uninfected_JJ ._SENT In_IN addition_NN to_TO MHC_NP class_NN I_PP ,_, KSHV_NP infection_NN of_IN T4_NP TIME_NN cells_NNS also_RB led_VBD to_TO surface_VB downregulation_NN of_IN PE-CAM_NP (_( CD31_NP )_) and_CC ICAM-1_NP (_( CD54_NP )_) (_( Fig._NN and_CC C_NP ,_, respectively_RB )_) ._SENT These_DT two_CD proteins_NNS ,_, normally_RB expressed_VBN on_IN endothelial_JJ cells_NNS ,_, provide_VB adhesion_NN and_CC costimulatory_JJ signaling_VBG to_TO CTLs_NP during_IN T-cell-endothelial_NP cell_NN interactions_NNS ._SENT Furthermore_RB ,_, inhibition_NN of_IN these_DT signaling_VBG pathways_NNS greatly_RB reduces_VBZ the_DT ability_NN of_IN CTLs_NP to_TO kill_VB target_NN cells_NNS ._SENT In_IN contrast_NN ,_, KSHV_NP infection_NN of_IN T4_NP TIME_NN cells_NNS led_VBD to_TO no_DT appreciable_JJ change_NN in_IN the_DT level_NN of_IN the_DT cell_NN surface_NN protein_NN LFA-3_NP (_( CD58_NP )_) while_IN slightly_RB increasing_VBG the_DT levels_NNS of_IN another_DT marker_NN ,_, Fas_NP (_( CD95_NP )_) (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT findings_NNS argue_VBP that_IN the_DT downregulation_NN of_IN MHC_NP class_NN I_PP ,_, ICAM-1_NP ,_, and_CC PE-CAM_NP during_IN infection_NN is_VBZ specific_JJ and_CC not_RB merely_RB a_DT reflection_NN of_IN global_JJ or_CC indiscriminant_JJ downregulation_NN ._SENT To_TO investigate_VB the_DT kinetics_NN of_IN immunoregulatory_JJ protein_NN downregulation_NN ,_, we_PP measured_VBD cell_NN surface_NN expression_NN of_IN MHC_NP class_NN I_PP ,_, PE-CAM_NP ,_, ICAM-1_NP ,_, and_CC LFA-3_NP on_IN T4_NP TIME_NN cells_NNS at_IN 12-h_NP intervals_NNS following_VBG de_NP novo_NN infection_NN with_IN KSHV_NP ._SENT For_IN MHC_NP class_NN I_PP ,_, downregulation_NN was_VBD not_RB evident_JJ at_IN 0_CD (_( not_RB shown_VBN )_) or_CC 12_CD h_NN postinfection_NN ._SENT However_RB ,_, downregulation_NN was_VBD apparent_JJ by_IN 24_CD h_NN and_CC reached_VBD its_PP$ peak_NN by_IN 48_CD h_NN ._SENT In_IN contrast_NN ,_, LFA-3_NP levels_NNS remained_VBD unchanged_JJ or_CC slightly_RB elevated_VBD throughout_IN this_DT period_NN ._SENT PE-CAM_NP and_CC ICAM-1_NP downregulation_NN kinetics_NNS (_( not_RB shown_VBN )_) were_VBD similar_JJ to_TO those_DT of_IN MHC_NP class_NN I._NN For_IN all_DT three_CD proteins_NNS ,_, cell_NN surface_NN levels_NNS at_IN 72_CD h_NN (_( not_RB shown_VBN )_) postinfection_NN were_VBD similar_JJ to_TO those_DT at_IN 48_CD h_NN ,_, suggesting_VBG that_IN a_DT new_JJ ,_, lower_JJR expression_NN set_NN point_NN may_MD have_VB been_VBN established_VBN ._SENT By_IN 96_CD h_NN postinfection_NN ,_, however_RB ,_, the_DT percentage_NN of_IN LANA-positive_JJ cells_NNS within_IN the_DT culture_NN began_VBD to_TO decrease_VB (_( see_VB above_IN )_) ._SENT This_DT led_VBD to_TO a_DT concomitant_JJ reduction_NN in_IN the_DT number_NN of_IN cells_NNS that_WDT exhibited_VBD downregulation_NN of_IN immunoregulatory_JJ proteins_NNS ,_, although_IN the_DT profile_NN of_IN proteins_NNS affected_VBN on_IN these_DT individual_JJ cells_NNS was_VBD unchanged_JJ from_IN that_DT at_IN the_DT earlier_JJR times_NNS ._SENT Apoptosis_NN was_VBD not_RB directly_RB responsible_JJ for_IN a_DT decrease_NN in_IN the_DT proportion_NN of_IN cells_NNS downregulating_VBG immunoregulatory_JJ proteins_NNS ,_, since_IN greater_JJR than_IN 97_CD %_NN percent_NN of_IN all_DT cells_NNS exhibiting_VBG downregulation_NN were_VBD viable_JJ ,_, as_RB evidenced_VBN by_IN a_DT lack_NN of_IN annexin_NN V_CD reactivity_NN (_( data_NNS not_RB shown_VBN )_) ._SENT At_IN all_DT times_NNS ,_, the_DT proportion_NN of_IN cells_NNS exhibiting_VBG surface_NN protein_NN downregulation_NN correlated_VBD directly_RB with_IN the_DT proportion_NN of_IN KSHV-infected_NP (_( LANA-positive_NP )_) cells_NNS within_IN the_DT culture_NN (_( data_NNS not_RB shown_VBN )_) ._SENT These_DT findings_NNS suggest_VBP that_IN direct_JJ infection_NN with_IN KSHV_NP may_MD be_VB required_VBN to_TO induce_VB downregulation_NN on_IN cells_NNS within_IN the_DT mixed_JJ culture_NN ._SENT However_RB ,_, they_PP do_VBP not_RB exclude_VB the_DT possibility_NN that_IN downregulation_NN may_MD be_VB variable_JJ on_IN infected_JJ cells_NNS and_CC that_DT soluble_JJ paracrine_NN factors_NNS or_CC direct_JJ cell-to-cell_NN contact_NN may_MD contribute_VB to_TO similar_JJ changes_NNS on_IN uninfected_JJ neighboring_JJ cells_NNS ._SENT To_TO investigate_VB the_DT possibility_NN of_IN a_DT paracrine_NN effect_NN ,_, we_PP incubated_VBD naive_JJ T4_NP TIME_NN cells_NNS for_IN 48_CD h_NN with_IN virus-cleared_JJ medium_NN removed_VBN from_IN a_DT culture_NN of_IN T4_NP TIME_NN cells_NNS infected_VBN with_IN KSHV_NP 48_CD h_NN earlier_JJR (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT Flow_NN cytometry_NN of_IN cells_NNS treated_VBN with_IN this_DT conditioned_VBN medium_NN ,_, however_RB ,_, revealed_VBD no_DT downregulation_NN of_IN any_DT of_IN the_DT cell_NN surface_NN proteins_VBZ that_IN we_PP tested_VBD ._SENT Instead_RB ,_, treatment_NN of_IN naive_JJ cells_NNS with_IN conditioned_VBN medium_NN from_IN KSHV-infected_NP cells_NNS led_VBD to_TO a_DT modest_JJ upregulation_NN of_IN ICAM-1_NP and_CC PE-CAM_NP ._SENT These_DT findings_NNS may_MD reflect_VB a_DT response_NN to_TO proinflammatory_JJ cytokines_NNS potentially_RB released_VBN by_IN cells_NNS within_IN the_DT KSHV-infected_NP culture_NN ._SENT In_IN any_DT case_NN ,_, these_DT results_NNS indicate_VBP that_IN soluble_JJ factors_NNS are_VBP not_RB sufficient_JJ to_TO elicit_VB downregulation_NN in_IN uninfected_JJ cells_NNS ._SENT However_RB ,_, cell-to-cell_NN contact_NN ,_, as_IN a_DT mechanism_NN of_IN downregulation_NN ,_, remained_VBD a_DT formal_JJ possibility_NN ._SENT Addressing_VBG this_DT question_NN required_VBD a_DT method_NN to_TO distinguish_VB infected_JJ from_IN uninfected_JJ cells_NNS within_IN a_DT mixed_JJ population_NN while_IN simultaneously_RB measuring_VBG levels_NNS of_IN cell_NN surface_NN proteins_NNS ._SENT Development_NN of_IN flow_NN cytometric_JJ approach_NN to_TO identify_VB KSHV-infected_NP cells_NNS ._SENT |_SYM Since_IN the_DT downregulation_NN of_IN immunomodulatory_JJ proteins_NNS by_IN KSHV_NP did_VBD not_RB appear_VB to_TO involve_VB paracrine_NN effects_NNS ,_, we_PP next_RB tested_VBD if_IN the_DT effects_NNS were_VBD dependent_JJ on_IN direct_JJ infection_NN with_IN KSHV_NP ._SENT To_TO investigate_VB this_DT possibility_NN ,_, we_PP developed_VBD a_DT flow_NN cytometric_JJ approach_NN ,_, similar_JJ to_TO that_DT described_VBN by_IN Kellam_NP et_FW al._FW ,_, to_TO identify_VB KSHV-positive_NP cells_NNS following_VBG de_NP novo_NP infection_NN ._SENT As_IN a_DT marker_NN of_IN infection_NN ,_, we_PP chose_VBD to_TO monitor_VB the_DT expression_NN of_IN LANA_NP because_IN it_PP is_VBZ an_DT abundant_JJ viral_JJ protein_NN expressed_VBN in_IN all_DT KSHV-infected_NP cells_NNS ._SENT We_PP first_RB conjugated_VBD the_DT highly_RB reactive_JJ fluorochrome_NN Alexa_NP 488_CD to_TO an_DT anti-LANA_NP rat_NN monoclonal_NN antibody_NN to_TO identify_VB LANA-expressing_NP cells_NNS in_IN culture_NN and_CC then_RB devised_VBD a_DT fixative_JJ process_NN to_TO detect_VB LANA_NP expression_NN in_IN the_DT nucleus_NN while_IN preserving_VBG membrane_NN integrity_NN for_IN cell_NN surface_NN analysis_NN (_( see_VB Materials_NNS and_CC Methods_NNS )_) ._SENT To_TO validate_VB this_DT approach_NN ,_, we_PP tested_VBD the_DT ability_NN of_IN this_DT conjugated_JJ antibody_NN to_TO detect_VB LANA_NP expression_NN within_IN the_DT KSHV-infected_NP BCBL-1_NP cell_NN line_NN by_IN flow_NN cytometry_NN ._SENT Greater_JJR than_IN 95_CD %_NN of_IN BCBL-1_NP cells_NNS were_VBD positive_JJ for_IN LANA_NP with_IN this_DT technique_NN ,_, while_IN the_DT reactivity_NN of_IN the_DT same_JJ antibody_NN with_IN the_DT KSHV-uninfected_NP B-cell_NN line_NN BJAB_NP was_VBD minimal_JJ ._SENT Furthermore_RB ,_, fluorescent_JJ microscopy_NN revealed_VBD that_IN BCBL-1_JJ cells_NNS prepared_VBN for_IN flow_NN cytometric_JJ analysis_NN with_IN the_DT fluorescently_RB labeled_VBN LANA_NP antibody_NN exhibited_VBD the_DT speckled_VBN nuclear_JJ staining_VBG pattern_NN that_WDT is_VBZ characteristic_JJ of_IN the_DT LANA_NP immunofluorescence_NN assay_NN (_( Fig._NN ,_, inset_NN )_) (_( -_: ,_, )_) ._SENT We_PP next_RB used_VBD this_DT approach_NN to_TO identify_VB newly_RB infected_JJ T4_NP TIME_NN cells_NNS following_VBG KSHV_NP infection_NN ._SENT LANA-specific_JJ flow_NN cytometry_NN detected_VBD evidence_NN of_IN KSHV_NP infection_NN of_IN T4_NP TIME_NN cells_NNS within_IN 24_CD h_NN of_IN their_PP$ incubation_NN with_IN the_DT virus_NN ._SENT Dot_NN plot_NN analysis_NN demonstrated_VBD a_DT marked_JJ shift_NN in_IN fluorescence_NN in_IN a_DT subset_NN of_IN the_DT cells_NNS that_WDT stained_VBD brightly_RB for_IN LANA_NP (_( Fig._NN ,_, gate_NN R3_NP )_) ._SENT The_DT mean_JJ fluorescence_NN intensity_NN of_IN infected_JJ cells_NNS was_VBD also_RB well_RB above_IN the_DT background_NN of_IN mock-infected_JJ cells_NNS ._SENT In_IN subsequent_JJ experiments_NNS ,_, we_PP compared_VBD cells_NNS with_IN the_DT highest_JJS (_( top_NN 25_CD %_NN )_) LANA_NP signal_VBP (_( Fig._NN ,_, gate_NN R3_NP )_) to_TO those_DT with_IN the_DT lowest_JJS (_( bottom_NN 25_CD %_NN )_) (_( Fig._NN ,_, gate_NN R2_NN )_) to_TO unambiguously_RB delineate_VB any_DT potential_JJ differences_NNS in_IN the_DT surface_NN protein_NN expression_NN profile_NN of_IN infected_JJ versus_CC uninfected_JJ cells_NNS ._SENT The_DT latter_JJ group_NN stained_VBN with_IN the_DT same_JJ low_JJ intensity_NN as_IN naive_JJ cells_NNS and_CC therefore_RB likely_RB represented_VBN only_JJ background_NN staining_VBG ._SENT This_DT strict_JJ gating_VBG approach_NN allowed_VBD us_PP to_TO focus_VB on_IN KSHV-infected_NP (_( LANA-positive_NP )_) cells_NNS in_IN the_DT culture_NN while_IN minimizing_VBG potentially_RB confounding_VBG effects_NNS from_IN background_NN fluorescence_NN ._SENT Of_IN note_NN ,_, in_IN determining_VBG absolute_JJ infection_NN rates_NNS ,_, this_DT flow_NN cytometric_JJ technique_NN ,_, although_IN specific_JJ for_IN KSHV-infected_NP cells_NNS ,_, was_VBD less_RBR sensitive_JJ than_IN parallel_JJ immunofluorescence_NN assays_NNS with_IN the_DT same_JJ anti-LANA_NN monoclonal_NN antibody_NN ._SENT This_DT difference_NN likely_RB reflects_VBZ the_DT advantage_NN of_IN the_DT immunofluorescence_NN assay_NN over_IN flow_NN cytometry_NN in_IN distinguishing_VBG between_IN the_DT distinct_JJ intranuclear_JJ ,_, punctate_JJ LANA_NP staining_VBG pattern_NN and_CC nonspecific_JJ background_NN fluorescence_NN ._SENT As_IN a_DT result_NN ,_, we_PP used_VBD an_DT anti-LANA_NP immunofluorescence_NN assay_NN in_IN each_DT experiment_NN to_TO more_RBR accurately_RB assess_VB overall_JJ infection_NN rates_NNS ._SENT Downregulation_NN of_IN MHC_NP class_NN I_PP ,_, PE-CAM_NP ,_, and_CC ICAM-1_NP on_IN KSHV-infected_NP T4_NP TIME_NN cells_NNS ._SENT |_SYM We_PP next_RB investigated_VBD whether_IN the_DT cells_NNS that_WDT exhibited_VBD immunoregulatory_JJ protein_NN downregulation_NN tracked_VBN with_IN the_DT population_NN that_WDT gated_VBD as_IN LANA_NP positive_JJ by_IN flow_NN cytometry_NN ._SENT KSHV_NP infection_NN of_IN T4_NP TIME_NN cells_NNS followed_VBN by_IN staining_VBG for_IN both_DT intranuclear_JJ LANA_NP and_CC surface_NN proteins_NNS demonstrated_VBD that_IN increased_VBN expression_NN of_IN LANA_NP generally_RB correlated_VBD with_IN lower_JJR expression_NN of_IN MHC_NP class_NN I_PP ,_, shifting_VBG the_DT population_NN from_IN the_DT upper_JJ left_JJ quadrant_NN (_( low_JJ LANA/high_NP MHC_NP class_VBP I_PP )_) to_TO the_DT lower_JJR right_NN quadrant_NN (_( high_JJ LANA/low_NP MHC_NP class_VBP I_PP )_) in_IN flow_NN cytometry_NN analyses_NNS ._SENT A_DT similar_JJ association_NN was_VBD also_RB evident_JJ between_IN LANA_NP expression_NN and_CC the_DT downregulation_NN of_IN PE-CAM_NP and_CC ICAM-1_NP ,_, although_IN ICAM-1_JJ downregulation_NN was_VBD also_RB present_JJ in_IN cells_NNS with_IN intermediate_JJ to_TO low_JJ LANA_NP expression_NN ._SENT In_IN contrast_NN ,_, LFA-3_NP surface_NN expression_NN remained_VBD essentially_RB unchanged_JJ in_IN the_DT same_JJ population_NN ,_, showing_VBG no_DT correlation_NN with_IN LANA_NP expression_NN ._SENT Although_IN these_DT data_NNS suggested_VBD a_DT trend_NN between_IN level_NN of_IN LANA_NP expression_NN and_CC downregulation_NN of_IN MHC_NP class_NN I_PP ,_, PE-CAM_NP ,_, and_CC ,_, to_TO a_DT lesser_JJR extent_NN ,_, ICAM-1_NP ,_, the_DT lack_NN of_IN signal_NN intensity_NN from_IN intranuclear_JJ LANA_NP fluorescence_NN in_IN our_PP$ flow_NN cytometry_NN assay_NN prevented_VBD a_DT more_RBR definitive_JJ assessment_NN of_IN this_DT relationship_NN ._SENT Specifically_RB ,_, the_DT LANA_NP flow_NN cytometry_NN assay_NN was_VBD unable_JJ to_TO separate_VB sufficiently_RB infected_JJ cells_NNS with_IN intermediate_JJ levels_NNS of_IN LANA_NP signal_NN from_IN uninfected_JJ cells_NNS with_IN similar_JJ but_CC nonspecific_JJ background_NN fluorescence_NN (_( note_VB the_DT overlap_VBP in_IN LANA_NP staining_VBG between_IN KSHV-infected_NP and_CC mock-infected_JJ cells_NNS in_IN Fig._NN ._SENT )_) Therefore_RB ,_, in_IN subsequent_JJ experiments_NNS ,_, we_PP used_VBD the_DT strict_JJ gating_VBG approach_NN shown_VBN in_IN Fig._NN to_TO compare_VB downregulation_NN between_IN the_DT cells_NNS exhibiting_VBG the_DT greatest_JJS (_( top_NN 25_CD %_NN )_) and_CC the_DT least_JJS (_( bottom_NN 25_CD %_NN )_) LANA_NP fluorescence_NN intensity_NN and_CC excluded_VBD the_DT remainder_NN of_IN the_DT cells_NNS for_IN which_WDT the_DT LANA_NP signal_NN overlapped_VBN with_IN background_NN staining_VBG exhibited_VBN on_IN mock-infected_JJ cells_NNS ._SENT This_DT gating_VBG focused_VBD the_DT comparison_NN between_IN the_DT populations_NNS that_IN most_RBS likely_RB represented_VBN infected_JJ and_CC uninfected_JJ cells_NNS ._SENT Using_VBG four-color_JJ flow_NN cytometric_NN staining_VBG ,_, we_PP identified_VBD a_DT close_JJ association_NN between_IN the_DT downregulation_NN of_IN MHC_NP class_NN I_PP and_CC the_DT downregulation_NN of_IN both_DT PE-CAM_NP and_CC ICAM-1_NP (_( but_CC not_RB LFA-3_NP )_) following_VBG KSHV_NP infection_NN ,_, suggesting_VBG that_IN these_DT processes_NNS arise_VBP on_IN a_DT similar_JJ population_NN of_IN cells_NNS (_( Fig._NN ,_, second_JJ column_NN ,_, lower_JJR left_NN quadrants_NNS )_) ._SENT To_TO determine_VB whether_IN this_DT population_NN comprised_VBN infected_JJ or_CC uninfected_JJ cells_NNS in_IN the_DT mixed_JJ culture_NN ,_, we_PP stained_VBD T4_NP TIME_NN cells_NNS for_IN both_DT cell_NN surface_NN protein_NN expression_NN and_CC intranuclear_JJ LANA_NP expression_NN and_CC gated_VBN on_IN cells_NNS with_IN the_DT highest_JJS (_( top_NN 25_CD %_NN )_) and_CC lowest_JJS (_( bottom_NN 25_CD %_NN )_) LANA_NP signal_NN as_RB described_VBD above_IN ._SENT We_PP found_VBD that_IN the_DT bulk_NN of_IN the_DT KSHV-infected_NP population_NN (_( highest_JJS LANA_NP expressers_NNS )_) exhibited_VBN downregulation_NN of_IN MHC_NP class_NN I_PP ,_, PE-CAM_NP ,_, and_CC ICAM-1_NP ,_, as_RB evidenced_VBN by_IN a_DT shift_NN in_IN the_DT cell_NN population_NN from_IN the_DT upper_JJ right_JJ quadrant_NN to_TO the_DT lower_JJR left_NN quadrant_NN (_( Fig._NN ,_, compare_VBP the_DT third_JJ and_CC fourth_JJ columns_NNS )_) ._SENT Approximately_RB 70_CD %_NN of_IN KSHV-infected_NP (_( LANA-positive_NP )_) cells_NNS exhibited_VBD downregulation_NN of_IN MHC_NP class_NN I_PP ,_, while_IN less_JJR than_IN 3_CD %_NN of_IN the_DT same_JJ population_NN showed_VBD downregulation_NN of_IN LFA-3_NP (_( Fig._NN ,_, fourth_JJ column_NN )_) ._SENT In_IN addition_NN ,_, codownregulation_NN of_IN MHC_NP class_VBP I_PP with_IN PE-CAM_NP and_CC ICAM-1_NP was_VBD pronounced_VBN on_IN the_DT high_JJ LANA_NP expressers_NNS but_CC only_RB minimal_JJ on_IN the_DT low_JJ LANA_NP expressers_NNS (_( Fig._NN ,_, compare_VBP the_DT third_JJ and_CC fourth_JJ columns_NNS ,_, lower_JJR left_NN quadrants_NNS )_) ._SENT Together_RB ,_, these_DT results_NNS indicate_VBP that_IN the_DT downregulation_NN of_IN immunoregulatory_JJ proteins_NNS occurs_VBZ preferentially_RB on_IN cells_NNS directly_RB infected_VBN with_IN KSHV_NP (_( highest_JJS LANA_NP expressers_NNS )_) ._SENT Primary_JJ DMVEC_NP infected_VBN by_IN coculture_NN display_VBP similar_JJ patterns_NNS of_IN MHC_NP class_NN I_PP ,_, PE-CAM_NP ,_, and_CC ICAM-1_NP downregu_NP 